Correct diagnosis of BD can prevent ocular and spinal disability when identified early and treated aggressively. Features of elevated serum or cerebrospinal lactate, absence of cerebrospinal pleocytosis, and aquaporin-4/myelin oligodendrocyte glycoprotein antibody negativity in a child with NMOSD clinical phenotype should prompt evaluation for BD. Further, use of immunomodulatory therapies may cause clinical worsening, although modest steroid responsiveness has been reported.2,3

Jonathan D. Santoro, MD
Kelli C. Paulsen, RN

Author Affiliations: Division of Neurology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California (Santoro, Paulsen); Department of Neurology, Keck School of Medicine at the University of Southern California, Los Angeles (Santoro).

Corresponding Author: Jonathan D. Santoro, MD, Division of Neurology, Children's Hospital Los Angeles, Keck School of Medicine at USC, 4650 Sunset Blvd, MS82, Los Angeles, CA 90027 (jdsantoro@chla.usc.edu).

Children's Hospital Los Angeles, Keck School of Medicine at USC, 4650 Sunset Blvd, MS82, Los Angeles, CA 90027 (jdsantoro@chla.usc.edu).

Published Online: October 5, 2020. doi:10.1001/jamaneurol.2020.3558

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patient's family for granting permission to publish this information.


CORRECTION

Correction to Author’s Academic Degrees: In the Original Investigation titled “Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease,” published online September 28, 2020, the academic degree for author Kathrin Doppler was incorrect and was updated to MD. A PhD degree had been erroneously included and has been removed. This article was corrected online.


Errors in Table 2 and Table 3: In the Original Investigation titled “Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis,” published online July 27, 2020, there were errors in Table 2 and Table 3. In each table, the variable given in the first column as “Proportion of patients with early RRMS receiving DMT (per 25% increase)” should have been “Proportion of time spent receiving DMTs during early RRMS (per 25% increase),” and the variable given as “Proportion of patients with SPMS receiving DMT (per 25% increase)” should have been “Proportion of time spent receiving DMTs during SPMS (per 25% increase).” This article was corrected online.


Error in P Value in Abstract and Results: The Original Investigation titled “Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial,” published online October 19, 2020, was corrected to fix an erroneous P value in the Abstract and the Results section. This article was corrected online.


Error in Data in Abstract: The Original Investigation titled “A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack: A Systematic Review and Meta-analysis,” published online October 12, 2020, was corrected to fix some percentages that had been transposed in the Results paragraph of the Abstract. This article was corrected online.


Error in Data in Abstract: The Original Investigation titled “Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial,” published online October 19, 2020, was corrected to fix some percentages that had been transposed in the Results paragraph of the Abstract. This article was corrected online.